Related Experiment Video

Updated: Aug 6, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Optimizing treatment for HER2-positive HR-positive breast cancer

Veronique Debien1, Evandro de Azambuja1, Martine Piccart-Gebhart2

  • 1Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team, Brussels, Belgium.

Cancer Treatment Reviews
|March 15, 2023
PubMed

Insights

Triple-positive breast cancer, overexpressing HER2 and HR, benefits from dual anti-HER2 blockade and endocrine therapy. Research explores optimizing treatments and identifying biomarkers for better disease control.

Area of Science:

  • Oncology
  • Breast Cancer Research

Background:

  • Triple-positive breast tumors overexpress human epidermal growth factor receptor 2 (HER2) and hormone receptors (HR).
  • Estrogen receptor (ER) expression influences treatment response in HER2-positive breast cancers receiving anti-HER2 and systemic therapies.

Purpose of the Study:

  • To review systemic treatment efficacy in triple-positive breast cancer from clinical trials.
  • To explore future research directions and potential biomarkers for triple-positive breast cancer.

Main Methods:

  • Review of clinical trial data on systemic treatment efficacy.
  • Analysis of preclinical and clinical data on endocrine therapy and anti-HER2 drug combinations.

Main Results:

  • Triple-positive breast cancers show decreased response rates compared to HR-negative/HER2-positive subtypes.
  • Combinations of endocrine therapy and anti-HER2 drugs demonstrate clinical efficacy.
  • Dual anti-HER2 blockade is crucial for optimal disease control.

Conclusions:

  • Optimizing anti-HER2 treatment with dual blockade is vital for triple-positive breast cancer.
  • Molecular insights may reveal new therapeutic strategies and biomarkers.
  • Further research is needed to refine treatment approaches for this subtype.
Keywords:
Anti-HER2 therapyAntibody-drug conjugateBiomarkersClinical trialsEndocrine therapyHER2-positive breast cancerMonoclonal antibodyTyrosine kinase inhibitor

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K